Nanologica Balance Sheet Health

Finanzielle Gesundheit Kriterienprüfungen 2/6

Nanologica hat ein Gesamteigenkapital von SEK10.9M und eine Gesamtverschuldung von SEK60.6M, was einen Verschuldungsgrad von 558.2% ergibt. Die Gesamtaktiva und Gesamtpassiva betragen SEK107.9M bzw. SEK97.1M.

Wichtige Informationen

419.8%

Verhältnis von Schulden zu Eigenkapital

SEK 60.68m

Verschuldung

Zinsdeckungsgrad	n/a
Bargeld	SEK 15.08m
Eigenkapital	SEK 14.46m
Gesamtverbindlichkeiten	SEK 91.76m
Gesamtvermögen	SEK 106.22m

Jüngste Berichte zur Finanzlage

Recent updates

Nanologica (STO:NICA) Is Making Moderate Use Of Debt

Oct 10

Is Nanologica AB (publ) (STO:NICA) Trading At A 40% Discount?

Jun 12

Does Nanologica (STO:NICA) Have A Healthy Balance Sheet?

Oct 20

Nanologica (STO:NICA) Is Making Moderate Use Of Debt

Jun 23

Is Nanologica (NGM:NICA) A Risky Investment?

Jan 03

Is Nanologica (NGM:NICA) Weighed On By Its Debt Load?

Jun 14

Shareholders Are Thrilled That The Nanologica (NGM:NICA) Share Price Increased 115%

Feb 23

Analyse der Finanzlage

Kurzfristige Verbindlichkeiten: NICADie kurzfristigen Aktiva des Unternehmens (SEK70.1M) übersteigen seine kurzfristigen Passiva (SEK35.8M).

Langfristige Verbindlichkeiten: NICADie kurzfristigen Vermögenswerte des Unternehmens (SEK70.1M) übersteigen seine langfristigen Verbindlichkeiten (SEK61.2M).

Geschichte und Analyse des Verhältnisses von Schulden zu Eigenkapital

Verschuldungsgrad: NICADie Nettoverschuldung im Verhältnis zum Eigenkapital (340.9%) wird als hoch angesehen.

Schulden abbauen: NICADas Verhältnis von Schulden zu Eigenkapital ist in den letzten 5 Jahren von 21.6% auf 558.2% gestiegen.

Bilanz

Liquiditätsreserve-Analyse

Bei Unternehmen, die in der Vergangenheit im Durchschnitt Verluste gemacht haben, wird geprüft, ob sie über einen Liquiditätsvorlauf von mindestens einem Jahr verfügen.

Stabile Start- und Landebahn für Bargeld: NICA hat auf der Grundlage seines derzeitigen freier Cashflows weniger als ein Jahr Liquiditätsspielraum.

Vorhersage Cash Runway: NICA hat weniger als ein Jahr Liquiditätsreserven, wenn der freie Cashflow weiterhin mit den historischen Raten von 18% pro Jahr abnimmt

Nanologica Balance Sheet Health

Finanzielle Gesundheit Kriterienprüfungen 2/6

Wichtige Informationen

Jüngste Berichte zur Finanzlage

Nanologica (STO:NICA) Is Making Moderate Use Of Debt

Does Nanologica (STO:NICA) Have A Healthy Balance Sheet?

Nanologica (STO:NICA) Is Making Moderate Use Of Debt

Is Nanologica (NGM:NICA) A Risky Investment?

Is Nanologica (NGM:NICA) Weighed On By Its Debt Load?

Recent updates

New major risk - Market cap size

Nanologica AB (Publ) Elects Alexandra Blomberg Montgomery as New Member of the Board of Directors

New major risk - Share price stability

New major risk - Financial position

Second quarter 2024 earnings released: kr0.25 loss per share (vs kr0.41 loss in 2Q 2023)

New major risk - Financial position

First quarter 2024 earnings released: kr0.46 loss per share (vs kr0.34 loss in 1Q 2023)

Nanologica AB (publ) Announces Chief Operating Officer Changes

New minor risk - Shareholder dilution

Full year 2023 earnings released: kr2.08 loss per share (vs kr1.84 loss in FY 2022)

Price target decreased by 25% to kr12.00

Full year 2023 earnings released: kr2.08 loss per share (vs kr1.84 loss in FY 2022)

Nanologica AB (publ) to Report Q2, 2024 Results on Jul 05, 2024

Insufficient new directors

New minor risk - Share price stability

Nanologica AB (publ) has filed a Follow-on Equity Offering in the amount of SEK 54.2 million.

New major risk - Financial position

Third quarter 2023 earnings released: kr0.32 loss per share (vs kr0.39 loss in 3Q 2022)

Nanologica AB (publ), Annual General Meeting, May 16, 2024

Nanologica AB (publ) Announces Nomination Committee for the Annual General Meeting 2024

Nanologica (STO:NICA) Is Making Moderate Use Of Debt

New minor risk - Financial position

Second quarter 2023 earnings released: kr0.41 loss per share (vs kr0.48 loss in 2Q 2022)

Is Nanologica AB (publ) (STO:NICA) Trading At A 40% Discount?

Chief Scientific Officer, Gary Pitcairn Will Leave Nanologica AB (publ)

First quarter 2023 earnings released: kr0.34 loss per share (vs kr0.56 loss in 1Q 2022)

Full year 2022 earnings: EPS and revenues miss analyst expectations

Insufficient new directors

No longer forecast to breakeven

Does Nanologica (STO:NICA) Have A Healthy Balance Sheet?

Second quarter 2022 earnings: EPS and revenues miss analyst expectations

Nanologica (STO:NICA) Is Making Moderate Use Of Debt

First quarter 2022 earnings: EPS and revenues miss analyst expectations

Price target decreased to kr16.50

No longer forecast to breakeven

Full year 2021 earnings: EPS exceeds analyst expectations while revenues lag behind

Full year 2021 earnings: EPS exceeds analyst expectations while revenues lag behind

Is Nanologica (NGM:NICA) A Risky Investment?

No longer forecast to breakeven

Third quarter 2021 earnings released: kr0.45 loss per share (vs kr0.32 loss in 3Q 2020)

Is Nanologica (NGM:NICA) Weighed On By Its Debt Load?

First quarter 2021 earnings released: kr0.28 loss per share (vs kr0.40 loss in 1Q 2020)

Full year 2020 earnings released: kr0.80 loss per share (vs kr1.18 loss in FY 2019)

Shareholders Are Thrilled That The Nanologica (NGM:NICA) Share Price Increased 115%

Nanologica Recruits PK Dutta as SVP Sales and Senior Advisor for Chromatography

New 90-day high: kr15.30

Nanologica AB (publ) Signs Collaboration Agreement with Zentiva for the Use of Nlab Drug Delivery Platforms

New 90-day high: kr13.80

Nanologica AB Engages Scientific Advisors Within Inhalation

Nanologica AB (Publ) Delivers Test Material from Large Scale Production

Nanologica AB (publ) to Report Q3, 2020 Results on Oct 30, 2020

New 90-day high: kr15.05

First half earnings released

New 90-day high - kr14.00

Nanologica AB (publ) to Report Q2, 2020 Results on Aug 21, 2020

Analyse der Finanzlage

Geschichte und Analyse des Verhältnisses von Schulden zu Eigenkapital

Bilanz

Liquiditätsreserve-Analyse

Entdecken Sie finanziell stabile Unternehmen